News

Emma speaking

A tribute to Emma…

Fundraising for Kick Sarcoma Foundation In Honor of Emma by TiffanyHuang Childhood cancer affects more than 15,000 kids per year, and claims the lives of a quarter of them. It rips away their hopes and dreams, brings them pain and suffering, and may even scar them forever, yet they share one thing – they never…

read more
technology-from-pixabay.com_

Infocus Survey

Chemotherapy-induced peripheral neuropathy (CIPN) is a condition that can have a huge effect on individuals following cancer treatment. However, little is known about its impact on a nation-wide level. If you have received chemotherapy that can cause CIPN, we invite you to take part in a nation-wide online survey.

read more

Size Matters For Sarcomas

Early diagnosis of sarcoma is key! One of the key factors that influences whether a soft tissue sarcoma can be successfully treated is the size of the tumour at diagnosis. The larger the tumour, the more difficult it is to treat and the lower the chance of getting a cure. Average survival is 50% at…

read more
14.-news-img3

Results of a phase II study of sirolimus and cyclophosphamide

Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma Schuetze SM et al. – Sirolimus and cyclophosphamide were tolerated by the majority of patients. About 20% of patients had stable sarcoma for at least 6months but objective tumour response was infrequent. Methods Patients received 4mg sirolimus daily and 200mg…

read more
14.-news-img2

(ZIOP.OB) Reports Positive Preliminary Palifosfamide Overall Survival Data

ZIOPHARM Oncology, Inc. (ZIOP.OB) Reports Positive Preliminary Palifosfamide Overall Survival Data From Randomized Phase 2 Study in Soft Tissue Sarcoma: NEW YORK, Feb. 13, 2012 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP – News), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, announced today positive preliminary overall survival (OS)…

read more
14.-news-img1

Votrient (Pazopanib) For Soft Tissue Sarcoma Approved By FDA

Votrient (pazopanib) has been approved by the FDA for the treatment of soft tissue sarcoma in patients who have already received chemotherapy. Soft tissue sarcoma is a type of cancer that starts in the fibrous tissue blood vessels, fat, muscle, or other supporting tissue in the body. The cancer develops in the mesenchymal cells. Votrient…

read more